Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.
(@ctong0)

Goal 2: Reduce Human Disease

Regeneration of Failing Heart while Resting on Left Ventricular Assist Device

Heart transplant is the ultimate treatment for AHA stage-D heart failure. Due to availability, heart transplants will be limited to about 2,500 per year. Patients with AHA stage-D heart failure has estimated prevalence of 0.2% for age >45. Thus, patients in need far exceed organs available. A failed heart has very challenging environment for cellular therapy. Left ventricular assist device (LVAD) can offload the heart ...more »

Voting

-4 net votes
3 up votes
7 down votes
Active
(@leonardo.brandao)

Goal 2: Reduce Human Disease

Understand the Impact of Thrombosis in Children with Cancer

CC: Despite the potential impact that venous thrombotic events (VTE) have on children with cancer, several unresolved issues remain. To date, we are yet to understand: - incidence/prevalence of VTE according to cancer type/staging - ideal imaging modalities to diagnose/follow VTE - thromboprophylaxis according to thrombosis risk stratification (development of VTE predictors) - efficacy/safety to anticoagulate children ...more »

Voting

30 net votes
38 up votes
8 down votes
Active
(@moshe.arditi)

Goal 2: Reduce Human Disease

More funding for Kawasaki Disease Vasculitis

Kawasaki Disease is the most common cause of acquired heart disease among children and we just started to understand that Kawasaki Disease 9 unrecognized during childhood) maybe responsible for a large number of adult atherosclerotic diseases and excellent animal models for this vasculitis exist and more funding should be allocated for this disease. We are now starting to understand that Kawasaki Disease is NOT a self ...more »

Voting

2 net votes
2 up votes
0 down votes
Active
(@skrenrich)

Goal 2: Reduce Human Disease

Patient Registries

Researchers at academic institutions, research foundations, and industry are poorly managing clinical data about patients they treat and enroll in clinical trials. A better coordinated patient registry effort related to heart, lung, and blood disease patients would yield long term benefits for clinical research and clinical care improvement.

Voting

5 net votes
8 up votes
3 down votes
Active
(@harmony.reynolds)

Goal 2: Reduce Human Disease

Improving understanding of heart attack mechanisms in women and targeting of treatment

There remain many differences between women and men in the risk of myocardial infarction (MI or “heart attack”), manifestations of MI and outcomes after MI. The time in which the facts about differences between the sexes were unknown or ignored has passed. However, there are many basic answers women and their physicians need, such as: a) Why are younger women with MI at such high risk of death as compared to their male ...more »

Voting

22 net votes
29 up votes
7 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Understanding Pathobiology of Exacerbations

COPD exacerbations contribute to poor quality of life, lung function and functional decline. In addition, they are costly to the patient and to health care cost. However, they remain defined exclusively on symptoms and constitute a “soft” endpoint. Actually, the number of exacerbations has become the GOLD standard to establish the risk of outcome (exacerbations). However, a mild episode that only requires outpatient ...more »

Voting

1 net vote
1 up votes
0 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

COPD hospitalizations

COPD hospitalizations a. Define the pathobiological changes that lead to severe exacerbations that cause hospitalizations b. Define novel clinical and biological phenotypic characterizations of hospitalized patients who fail treatment that results in death or early readmission c. Explore new or understudied therapies for treatment of acute COPD hospitalizations: antioxidant, non-steroidal anti-inflammatory (STATIN or ...more »

Voting

3 net votes
3 up votes
0 down votes
Active